Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31605249 | 0.87 | HPGDS (0.54) | LMNAMAPTHPGDSALDH1A1MRGPRX4 | |
| SCHEMBL1435371 | 0.87 | HPGDS (0.54) | LMNAMAPTHPGDSALDH1A1MRGPRX4 | |
| SCHEMBL9720636 | 0.85 | LMNA (0.65) | LMNAMAPK1MAPTALDH1A1KCNMA1 | |
| SCHEMBL10552875 | 0.85 | LMNA (0.60) | LMNAMAPK1MAPTALDH1A1KCNMA1 | |
| SCHEMBL20247900 | 0.83 | LMNA (0.59) | LMNAMAPK1MAPTALDH1A1KCNMA1 | |
| SCHEMBL2096737 | 0.83 | HPGDS (0.57) | LMNAMAPTHPGDSALDH1A1TSHR | |
| SCHEMBL3049895 | 0.83 | ALDH1A1 (0.44) | LMNAMAPK1MAPTHPGDSALDH1A1 | |
| SCHEMBL48961 | 0.82 | MRGPRX4 (0.64) | LMNAMAPK1MAPTALDH1A1KCNMA1 | |
| SCHEMBL30100412 | 0.82 | MRGPRX4 (0.64) | LMNAMAPK1MAPTALDH1A1KCNMA1 | |
| SCHEMBL8575954 | 0.82 | HTR2A (0.53) | LMNAMAPK1MAPTALDH1A1KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212636-B1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | disclosed |
| WO-2019063748-A1 | ROR-GAMMA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019063748-A1 | ROR-GAMMA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-04 | — | — | WO | disclosed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | disclosed |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-2789607-B1 | PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-2789607-B1 | PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | disclosed |
| US-7294644-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | MAYWEG ALEXANDER | 2007-10-11 | — | — | US | disclosed |
| EP-1658273-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1658273-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1658273-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1583742-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| WO-2005019184-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040167129-A1 | Novel CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004060870-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | FLT3, CSF1R, CSF3R | LMNA 4733/4885MAPK1 1387/4885MAPT 4788/4885 |
| US-10065937-B2 | FLT3 receptor antagonists | FLT3, CSF1R, CSF3R | LMNA 4733/4885MAPK1 1387/4885MAPT 4788/4885 |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | PNPO, PDXK, PLPBP | LMNA 2668/4885MAPK1 880/4885MAPT 3357/4885 |
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | LMNA 1315/4885MAPK1 2263/4885MAPT 3896/4885 |
| US-20040167129-A1 | Novel CB 1 receptor inverse agonists | CNR1, CNR2, ARRB1 | LMNA 3407/4885MAPK1 989/4885MAPT 4278/4885 |
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | CNR1, CNR2, GPR139 | LMNA 3597/4885MAPK1 1152/4885MAPT 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.